New 128,000-sq.-ft. facility in Andover will support the development and commercialization of ADVC001 and its pipeline of Lead-212 targeted alpha therapies.
Learn how innovation in excipients, solvents, and patient-centric design is propelling long-acting injectables from niche therapies to the forefront of modern drug delivery.
The multi-product oncology deal includes assets that have validated targets and aim to address efficacy and/or tolerability limitations of existing therapies.
Siegfried offers contract development and manufacturing of APIs, intermediates, and finished dosage forms. From early-phase development to commercial scale, its integrated approach ensures comprehensive services, including process development, registration, production, packaging, and logistics. Siegfried operates 13 facilities in 7 countries worldwide.
Eurofins Central Laboratory provides comprehensive safety, efficacy, biomarker, and pathology services through a global network of CAP-accredited laboratories, supporting clinical trials in more than 85 countries. Globally Harmonized, Personalized Partnership: We deliver the best of both worlds - you gain a trusted ally committed to your success.
